PTO/SB/08a (08-03) Approved for use through 07/31/2006, OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

002877.00028

no persons are required to respond to a collection of information unless it contains a valid OMB control number. Substitute for form 1449A/PT& Complete if Known Application Number 10/790,768 INFORMATION DISCLOSURE Filing Date March 3, 2004 STATEMENT BY APPLICANT First Named Inventor Michael Karas 1284> Art Unit (Use as many sheets as necessary) Examiner Name TBA-Anam

Attorney Docket Number

Sheet

of

			U.S. PATENT	DOCUMENTS	
Examiner Initials *	Cite	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant
	No.	Number - Kind Code ² (if known)	MM-DD-YYYY	Cited Document	Passages or Relevant Figures Appear
(- AF)		US- 5,652,122	07-29-1997	Frankel et al.	
		US- 5,670,617	09-23-1997	Frankel et al.	
		US- 5,674,980	10-07-1997	· Frankel et al.	
		US- 5,747,641	05-05-1998	Frankel et al.	
		US- 5,804,604	09-08-1998	Frankel et al.	
7		US- 5,807,746	09-15-1998	Lin et al.	
		US- 6,093,809	07-25-2000	Cech et al.	
		US- 6,166,178	12-26-2000	Cech et al.	
1		US- 6,261,836	07-17-2001	Cech et al.	
J /		US- 6,306,993	10-23-2001	Rothbard et al.	
	[US- 6,358,739	03-19-2002	Baetge et al.	
4		US- 2002-0009491 A1	01-24-2002	Rothbard et al.	
		US-			
	[US-			

Examiner Initials*	0110	Foreign Patent Document	Deblication	Name of Patentee or	Pages, Columns, Lines,	
	Cite No. ¹	Country Code ³ - Number ⁴ - Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T ^o
Æ		EP - 0 841 396 A1	05-13-1996	Cech et al.		•
.40		WO - 99/50386	10-07-1999	Morin		•
		WO - 00/34308	06-15-2000	Dowdy et al.		•
		WO - 00/61617	10-19-2000	Baetge et al.		
V		WO - 00/62067	10-19-2000	Dowdy		•
AD		WO - 01/15511	03-08-2001	Robbins et al.		•
				 -		

Examiner Signature	A	Q)_	Date Considered	2-	9-06)
						

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patient Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WiPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case, Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b(08-03) Approved for use through 07/31/2006, OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid QMB control number

Substitu	te for form 144	9B/PTO		Complete if Known				
INIT/	2084 A TI	ON DIC	OL OCUBE	Application Number	10/790,768			
INFORMATION DISCLOSURE				Filing Date	March 3, 2004			
STA	TEMEN	T BY A	PPLICANT	First Named Inventor	Michael Karas			
				Art Unit	1204-1653			
	(Use as ma	iny sheets as	necessary)	Examiner Name	TOA Apand Desai			
Sheet	2	of	2	Attorney Docket Number	002877.00028			

APITAL LETTERS), title of the article (when appropriate), title of I, serial, symposium, catalog, etc.), date, page(s), volume-issue ublisher, city and/or country where published.
, and evaluation of melecules that enable or enhance cellular uptake: 5, vol. 97, no. 24, November 21, 2000, pp. 13003-13008.
losa Cell-Specific Genes and Induction of Apoptosis in Conditionally blished from H-2K5-tsA58 Transgenic Mice" Biology of Reporduction, vol.
on Domains: Enhanced Transduction Potential in Vitro and in Vivo ¹ ** 2001, pp. 474-477.
nic brain injury by protein therapeutics" PNAS, vol. 99, no. 26, December
Fusion Protein Containing the TAT Protein Transduction Domain nd Neuronal Apoptosis" Jorunal of Neuroscience, vol. 22, no. 13, July 1,
ss - Linking: Homobifunctional Cross-linkers" http://www.piercenet.com
ss - Linking: Heterobifunctional Cross-linkers" http://www.piercenet.com
ss - Linking: Applications for Use of Cross-linkers"
ss - Linking: Glossary of Cross-finking Terms* http://www.piercenet.com

Examiner Signature ,	Dow	Date Considered	2-9-06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08a (08-03) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	CIHA		addit Mat at 1995, No persons	ale raquited to respond to a consecutive	S BALLIN DON COMPANY OF STREET	
Substitute	o for form 1448A/PTC	0		Complete if Known		
				Application Number	10/790,768	
INFO	RMATION	DIS	CLOSURE	Filing Date	March 3, 2004	
STA	TEMENT B	YA	PPLICANT	First Named Inventor	Michael KARAS	
				Art Unit	1646	
(Use as many sheets as necessary)				Examiner Name	TBA	
Sheet	1	of	1	Attorney Docket Number	002877.00028	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	τ;
JP.		CONEJERO et al., "Glutamate and Antimitotic Agents Induce Differentiation, p53 Activation, and Apoptosis in Rodent Neostriatal Cell Lines Immortalized with the tsA58 Allele of SV40 Large T Antigen," 1999, Experimental Neurology, Vol. 158, pp. 109-120.	
NE)	DERER et al., Direct Protein Transfer to Terminally Differentiated Muscle Cells, 1999, J. Mol. Med., Vol. 77, pp. 609-613. EXAMINER CLACING IN FILE	
A		GUENAL et al., "Bcl-2 and Hsp27 Act at Different Levels to Suppress Programmed Cell Death," 1997, Oncogene, Vol. 15, pp. 347-360.	
A0		KIM et al., "Survival of Conditionally Immortalized Hepatocytes in the Spleen of Syngeneic Rats," 2001, Journal of Gastroenterology and Hepatology, Vol. 18, pp. 52-60.	
10		MI et al., "Characterization of a Class of Cationic Peptides Able to Facilitate Efficient Protein Transduction in Vitro and in Vivo," October 2000, Molecular Therapy, Vol. 2, No. 4, pp. 339-347.	
AO		MORRIS et al., "A Peptide Carrier for the Delivery of Biologically Active Proteins into Mammalian Cells," December 2001, Nature Biotechnology, Vol. 19, pp. 1173-1176.	
D		SCHWARTZ& Zhang, "Peptide-Mediated Cellular Delivery," 2000, Current Opinion in Molecular Therapeutics, Vol. 2(2) (5 pages).	
1		URQUIDI et al., "Role of Telomerase in Cell Senescence and Oncogenesis," 2000, Ann. Rev. Med., Vol. 51, pp. 65-79.	
10		VOCERO-AKBANI et al., "Protein Transduction: Delivery of Tat-GTPase Fusion Proteins into Mammalian Cells," Regulators and Effectors of Small GTPases," Vol. 332, pp. 36-49, 2001.	
M		WADIA & Dowdy, "Protein Transduction Technology," 2002, Curr. Opin. Biotechnology, Vol. 13, pp. 52-56.	

						,		
Exan	niner ature	[j]		-	Date Considered	2-	9-06	
(3		1 / 4	$\underline{}$		1			

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation in not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. 1450.

PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute	for form 1449AR	desc	EMAE	Complete if Known				
				Application Number	10/790,768	_		
INFO	RMATION	DIS	CLOSURE	Filing Date	March 3, 2004			
STATEMENT BY APPLICANT				First Named Inventor	Michael KARAS			
				Art Unit	# 646 ° 1653			
	(Use as many she	ets as	necessary)	Exeminer Neme	TBAT Arand Dosas			
Sheet	1	of	1	Attorney Docket Number	002877.00028			

	,	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T2
AO		DIETZ ET AL., "Inhibition of Neuronal Apoptosis in Vitro and in Vivo Using TAT-Mediated Protein Transduction", Molecular and Cellular Neuroscience, 2002, pp 29-37, Vol. 21.	
10		FAWALL ET AL., "Tat-mediated delivery of heterologous proteins into cells", Biogen Inc., October 7, 1993, pp. 664-668.	
_		·	
		4	<u> </u>

Examiner Signature	S	\bigcirc	Date Considered	2-9-06

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

^{*}EXAMINER: Initial if reference considered, whether or not clation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.